pan-Canadian Pharmaceutical Alliance (pCPA): December 2019 Trends and Insights
The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the December 31, 2019 status of brand negotiations. Highlights since the last update include:
- 3 products completed CADTH review, for a total of 10 files under consideration;
- 0 products initiated pCPA negotiations, for a total of 32 active negotiations;
- 1 negotiation completed for a total of 295 completed negotiations;
- 1 negotiation closed, for a total of 48 closed negotiations; and
- 1 file closed without negotiations, for a total of 73 declined negotiations.
Files Under pCPA Consideration
3 new drug products received a CDEC recommendation or pERC notification to implement in December 2019, for a total of approximately 10 products under pCPA Consideration.
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation |
|---|---|---|---|---|
| Tegsedi* | Inotersen | Akcea Therapeutics | Hereditary Transthyretin Amyloidosis | Conditional |
| Lynparza | Olaparib | AstraZeneca | Ovarian Cancer | Conditional |
| Nerlynx | Neratinib | Knight Therapeutics | Hormone Receptor Positive Breast Cancer |
Does not recommend
|
*While this file received a CADTH recommendation in December, Tegsedi commenced negotiations in November 2019 following an August 2019 INESSS recommendation and therefore, has not been counted as an under-consideration file.
Signals Decoded:
Lynparza, which is already widely reimbursed as a maintenance treatment option in ovarian cancer, receives a conditional recommendation for use in newly diagnosed ovarian cancer. Tegsedi, which had negotiations initiated in November 2019, receives a conditional recommendation from CADTH.
Completed
The pCPA completed 1 negotiation since the last update for a total of 295 completed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Initiated | Duration* |
|---|---|---|---|---|---|
| Prevymis | Letermovir | Merck | Prevention of Cytomegalovirus Infection | Nov 2018 | 395 days |
Closed
The pCPA closed 1 negotiation since the last update for a total of 48 closed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Initiated | Duration* |
|---|---|---|---|---|---|
| Lutathera | Lutetium Lu-177 | Advanced Accelerator Applications | Midgut Neuroendocrine Tumours | Sep 2019 | 91 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Signals Decoded:
Of the 32 active negotiations, the 18 non-oncology files have been under active negotiation for an average of 235 calendar days as of December 15, 2019 (range: 30 to 944 days). The remaining 14 oncology files have been under active negotiation for an average of 201 calendar days as of December 15, 2019. (range: 30 to 487 days).
Not Negotiated
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Time to Decision* |
|---|---|---|---|---|---|
| Vitrakvi | Larotrectinib | Bayer | Locally Advanced or Metastatic Solid Tumors that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion | 15 Nov 19 | 30 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
